Millipore Sigma Vibrant Logo

SCC127 SF8628 Human DIPG H3.3-K27M Cell Line

SF8628 pediatric diffuse intrinsic pontine glioma (DIPG) cell line harbors the histone H3.3 Lys 27-to-methionine (K27M) mutation and can support research and drug development efforts targeting DIPG.

SF8628 Human DIPG H3.3-K27M Cell Line: MSDS (material safety data sheet) o SDS, certificato d’analisi (CoA) e certificato di qualità (CoQ), dossier, brochure e altri documenti disponibili.
Key Applications: Cell Culture
View Products on Sigmaaldrich.com
SCC127
≥1X10⁶ cells/vial  
Ricerca del prezzo in corso...
Non è stato possibile trovare il prezzo
La quantità minima deve essere un multiplo di
Maximum Quantity is
Al termine dell'ordine Maggiori informazioni
Lei ha salvato ()
 
—
Richiedi il prezzo
—
Disponibilità limitata Disponibilità limitata
A magazzino 
Fuori produzione
Disponibili quantità limitate
La disponibilità deve essere confermata
    Prodotti rimanenti: riceverà un nostro avviso
      Prodotti rimanenti: riceverà un nostro avviso
      Will advise
      Contatti il Servizio Clienti
      Contact Customer Service

       

      Contatti il Servizio Clienti

      Panoramica

      Replacement Information

      Tabella delle specifiche principali

      Key Applications
      CULT
      Description
      Catalogue NumberSCC127
      DescriptionSF8628 Human DIPG H3.3-K27M Cell Line
      OverviewSF8628 is a human glioma cell line derived by surgical biopsy from a pediatric H3.3K27M DIPG patient (6). This novel cell line may be used to facilitate the testing of specific targeted therapeutics for DIPG.
      Background InformationDiffuse intrinsic pontine gliomas (DIPG) are highly aggressive and difficult to treat tumors arising in the ventral pons of the brain stem. Despite therapeutic advances, DIPG is incurable and most patients, primarily children, die within 2 years of diagnosis. DIPG is one of the leading causes of death in children with brain tumors (1).

      A somatic mutation of histone H3.3 resulting in a lysine 27 to methionine substitution (H3.3K27M) occurs in 60% of DIPG (2). In H3.3K27M DIPG patient samples, levels of H3K27 dimethylation (H3K27me2) and trimethylation (H3K27me3) are reduced globally. These epigenetic changes are thought to be important factors driving DIPG oncogenesis (2,3,4). Expression of H3.3K27M was also recently shown to be associated with increased levels of H3K27 acetylation (H3K27ac) and recruitment of bromodomain proteins at sites of active transcription (5). Treatment of H3.3K27M DIPG cells with a bromodomain and extra-terminal domain (BET) inhibitor was found to inhibit proliferation and induced differentiation. BET inhibitors are thus a promising therapeutic approach for the treatment of DIPG.

      1. Schroeder KM et al. (2014) Pediatr. Res. 75(1-2): 205–209.
      2. Lewis PW et al. (2013) Science 340(6134): 857–861.
      3. Chan K-M et al. (2013) Genes & Development 27: 985-990.
      4. Hashizume R et al. (2014) Nat Med. 20(12):1394-6.
      5. Piunti A et al. (2017) Nat. Med. 23(4): 493-500.
      6. Mueller S et al. (2014) Neuro Oncol. 16(3): 352-360.
      References
      Product Information
      Quality LevelMQ100
      Applications
      ApplicationSF8628 pediatric diffuse intrinsic pontine glioma (DIPG) cell line harbors the histone H3.3 Lys 27-to-methionine (K27M) mutation and can support research and drug development efforts targeting DIPG.
      Key Applications
      • Cell Culture
      Application NotesThis product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact licensing@emdmillipore.com.
      Biological Information
      Cell Line Type
      • Cancer Cells
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality Assurance• Each vial contains ≥ 1X106 viable cells.
      • Cells are tested negative for Epstein-Barr virus, HPV-16, HPV-18, Hepatitis A, C, Herpesvirus type 6, 7, 8 and HIV-1 & 2 viruses by PCR
      • Cells are negative for mycoplasma contamination.
      • Each lot of cells is genotyped by STR analysis to verify the unique identity of the cell line
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStore in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.
      Packaging Information
      Material Size≥1X10⁶ cells/vial
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Numero di catalogo GTIN
      SCC127 04054839329937